Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF MEDICAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 69,922 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,497 · Balance 68,120 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,624 · Balance 69,744 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 71,494 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 73,951 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,029 · Balance 69,922 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,700 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 6,700 · Balance 6,700 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,500 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 3,500 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,624 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,624 · Balance 1,624 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,497 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 26,750 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 26,750 · Balance 26,750 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 3, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010077 · form4-04032024_090447.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,872 Underlying: Class A Common Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 477 | $19.70 | $9,396.90 |
DisclosureSEC source: 0001415889-24-010077 · form4-04032024_090447.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,039 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,624 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010077 · form4-04032024_090447.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 18,844 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-24-006674 · form4-03052024_090325.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,217 Underlying: Class A Common Shares · 18,844 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 18,844 | $21.77 | $410,233.88 |
DisclosureSEC source: 0001415889-24-006674 · form4-03052024_090325.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.21 to $22.07. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 18,844 | $1.86 | $35,049.84 |
DisclosureSEC source: 0001415889-24-006674 · form4-03052024_090325.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,156 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-24-005883 · form4-02292024_090213.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,061 Underlying: Class A Common Shares · 10,156 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 10,156 | $21.03 | $213,580.68 |
DisclosureSEC source: 0001415889-24-005883 · form4-02292024_090213.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 10,156 | $1.86 | $18,890.16 |
DisclosureSEC source: 0001415889-24-005883 · form4-02292024_090213.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 28,600 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,217 Underlying: Class A Common Shares · 28,600 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 1,501 | $17.81 | $26,732.81 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.80 to $17.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 6,702 | $17.75 | $118,960.50 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,393 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.70 to $17.795. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 13,017 | $17.64 | $229,619.88 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,095 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.60 to $17.695. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 7,380 | $17.54 | $129,445.20 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,112 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.595. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 28,600 | $1.86 | $53,196.00 |
DisclosureSEC source: 0001415889-23-016183 · form4-12112023_041201.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 400 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 11 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,817 Underlying: Class A Common Share · 400 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 400 | $17.53 | $7,012.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,892 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.56. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 400 | $1.86 | $744.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 10 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,450 Underlying: Class A Common Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 507 | $17.76 | $9,004.32 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,892 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 38,974 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 9 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,974 Underlying: Class A Common Share · 38,974 shares Expires 2033-08-31 F6 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,496 Underlying: Class A Common Share · 6,496 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. F6 · derivative.expiration_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,492 Underlying: Class A Common Share · 2,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 734 | $17.76 | $13,035.84 |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,674 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 29,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-23-011525 · form4-07272023_080730.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,217 Underlying: Class A Common Share · 29,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 7,632 | $19.69 | $150,274.08 |
DisclosureSEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,910 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.50 to $19.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 16,168 | $19.25 | $311,234.00 |
DisclosureSEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,542 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.50 to $19.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 5,200 | $18.01 | $93,652.00 |
DisclosureSEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,710 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $18.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 29,000 | $1.86 | $53,940.00 |
DisclosureSEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006443 · form4-04112023_090458.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,492 Underlying: Class A Common Share · 2,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 734 | $10.71 | $7,861.14 |
DisclosureSEC source: 0001415889-23-006443 · form4-04112023_090458.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,910 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006443 · form4-04112023_090458.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005791 · form4-04032023_040421.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 Underlying: Class A Common Share · 6,496 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 38,974 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005791 · form4-04032023_040421.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,974 Underlying: Class A Common Share · 38,974 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 3,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,078 | $11.12 | $11,987.36 |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,146 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,450 Underlying: Class A Common Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 507 | $11.46 | $5,810.22 |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,553 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005236 · form4-03202023_090359.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 28,357 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-22-011237 · form4-11092022_091158.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,217 Underlying: Class A Common Share · 28,357 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 28,357 | $15.18 | $430,459.26 |
DisclosureSEC source: 0001415889-22-011237 · form4-11092022_091158.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,335 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.00 to $15.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 28,357 | $1.86 | $52,744.02 |
DisclosureSEC source: 0001415889-22-011237 · form4-11092022_091158.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009350 · form4-09062022_010932.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,175 Underlying: Class A Common Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 507 | $11.44 | $5,800.08 |
DisclosureSEC source: 0001415889-22-009350 · form4-09062022_010932.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,335 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009350 · form4-09062022_010932.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009350 · form4-09062022_010932.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 Underlying: Class A Common Share · 9,990 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 59,930 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009350 · form4-09062022_010932.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,930 Underlying: Class A Common Share · 59,930 shares Expires 2032-08-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.